Navigation Links
Adoption of PCI in AMI Patients to Drive Drug-Eluting Stent Use
Date:2/18/2009

Nearly 150,000 PCIs Were Performed on AMI Patients in 2008, According to Millennium Research Group

WALTHAM, Mass., Feb. 18 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Interventional Cardiology Devices 2009 report, the use of drug-eluting stents will continue to climb steadily through 2013, driven in large part by the adoption of primary percutaneous coronary intervention (PCI) in Acute Myocardial Infarction (AMI) patients, who accounted for nearly 150,000 PCIs in the US in 2008.

In the past, primary PCI--defined as a PCI performed within 24 hours of the onset of symptoms--was mostly limited to facilities that had surgical back-up present. Studies have shown, however, that AMI patients who undergo primary PCI have improved outcomes over thrombolytics, even without surgical back-up. Experts are now trying to reduce the time it takes to get patients to a cath lab -- in some cases bypassing the emergency room -- which will drive primary PCI adoption and support DES use in AMI patients.

Furthermore, a number of clinical trials in 2007 and 2008 released positive clinical data, which showed that ST-elevation myocardial infarction (STEMI) patients who receive aspiration with stenting have better blood flow, enhanced myocardial function, and lower mortality rates than patients who received angioplasty with stenting or direct stenting.

"The TAPAS trial indicated that STEMI patients treated with aspiration prior to stenting had over 30% lower mortality in the following year compared to those who had angioplasty-with-stent procedures," says Stephanie LaBelle, Senior Analyst at MRG. "As a result, the portion of primary PCIs using aspiration rather than predilation prior to stenting will grow in AMI patients through 2013."

MRG's US Markets for Interventional Cardiology Devices 2009 report provides coverage of key industry trends, inc
'/>"/>

SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
2. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
3. American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks
4. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
5. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
6. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
7. CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year
8. Merck Seronos Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinsons Disease in a Phase III Pivotal Trial
9. First U.S. Patients Enrolled in the REALISM Continued Access Study
10. Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis
11. Study of Cannabinoid Medicine for Pain Found Patients Got High, but Effects Not Related to Pain Relief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, ... Guidance   ... including Core Earnings and ... Highlights of Q1 results  ... Underlying core earnings and underlying core EPS were flat, year-to-year , ...
(Date:7/29/2015)... Pa. , July 29, 2015  Unilife Corporation ... ASX: UNS), a developer, manufacturer and supplier of injectable ... multifaceted financing strategy that provides the Company with flexibility ... Unilife has signed an equity purchase agreement ... Fund, LLC ("LPC"), a Chicago -based ...
(Date:7/29/2015)... , July 29, 2015  Ascendis Pharma A/S ... that applies its innovative TransCon technology to address significant ... a conference call on July 30, 2015, at 9:00 ... a Phase 2 pediatric study of once-weekly TransCon Growth ... the top-line results before the market opens on July ...
Breaking Medicine Technology:Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 2Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 4Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 5Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time 2
... Kanghui Holdings (NYSE: KH ) ("Kanghui" or ... of orthopedic implants in China, today announced that all ... meeting held in Hong Kong on September 5, 2011 ... , Re-election of Mr. Yikang Jiang as a ...
... Discovery Labs, Inc. (Nasdaq: DSCO ) today ... Complete Response to the 2009 Complete Response Letter issued by ... (lucinactant) for the prevention of respiratory distress syndrome (RDS) ... will designate the Complete Response as a Class 2 ...
Cached Medicine Technology:China Kanghui Holdings Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting 2Discovery Labs Submits SURFAXIN® Complete Response to FDA 2Discovery Labs Submits SURFAXIN® Complete Response to FDA 3Discovery Labs Submits SURFAXIN® Complete Response to FDA 4
(Date:7/30/2015)... ... 2015 , ... Boston Web Marketing is proud ... Partners is the platform for search marketing agencies to communicate with the Google ... to run successful search marketing campaigns. Google Partners also affords businesses the opportunity ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is ... a nonsurgical treatment designed specifically for the elimination of excess tissue under ... first locations in the state of Wisconsin to offer this innovative treatment. , Developed ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Association of ... announcement of the reinstitution of National Prescription Drug Take-Back Days. The 10th event ... AM to 2:00 PM local time. On the 26th, the DEA, with the ...
(Date:7/30/2015)... NC (PRWEB) , ... July 30, 2015 , ... New ... patients. Click here to read more on the Surviving Mesothelioma website. ... Rehabilitation Hospital in Missouri reviewed more than 12,000 cases of mesothelioma occurring between 1990 ...
(Date:7/30/2015)... , ... July 30, 2015 , ... 1Heart Caregiver Services ... - “Learn How to Make Money in the Booming Homecare Business.” This will be ... 90010. , The event will be hosted by 1Heart’s very own ...
Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2
... April 18 An ex-White house aide,Robert Weiner, and ... cancer lab, are reporting that many scientists believe that ... a drop in real dollars for,cancer research, and private ... of the federal government." Discoveries are being,lost due to ...
... Coyote goes,hungry in cartoon land, it,s because Roadrunner ... Food Bank wins when nobody goes hungry., ... ), In that spirit, strategic communications firm ... to highlight the tragedy of hunger in New,Mexico ...
... showing the cancer may have an Achilles, heel, report suggests ... Gleevec has forced metastatic melanoma into remission for the first ... , The case involves a 79-year-old woman with melanoma tumors ... an abnormality in a gene called KIT, so the patient ...
... Family Research Council,Action applauds GOP Presidential candidate ... Villanova University supporting the pro-life,platform of the Republican ... of possible running mates., FRC Action,s Senior ... hear Senator McCain depict his support for life ...
... TSTF ), a national provider of healthcare and administrative,staffing ... of Shareholders held on April 17, 2008, at the ... annual meeting, shareholders approved the election of Rick J.,Filippelli ... Directors. In,addition, the Company,s shareholders also approved a proposal ...
... drugs had sharper declines in thinking skills, study finds ... known as anticholinergic drugs -- used to treat ulcers, ... -- may cause older people to lose their thinking ... medicines, new research suggests. , "What we found is ...
Cached Medicine News:Health News:Reduced Funds for Cancer is Cost of Iraq, Say Ex-White House Aide, Cancer Researchers 2Health News:BEEP BEEP!! Strategic Communications Firm DW Turner Thwarts Hunger in Partnership With Roadrunner Food Bank 2Health News:Gleevec Pushes Advanced Melanoma Into Remission 2Health News:FRC Action Praises John McCain's Pro-Life Comments 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 3Health News:Common Medications May Harm Memory in Older People 2Health News:Common Medications May Harm Memory in Older People 3
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
Inquire...
... Aerosol barrier tips eliminate false ... Scientifically designed and tested, Promega Barrier ... working with amplified nucleic acids (PCR(a)), ... samples, forensic and serological specimens. , ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
Medicine Products: